Navigation Links
ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
Date:4/8/2008

FREDERICK, Md., April 8, 2008 /PRNewswire/ -- ImQuest scientists Robert W. Buckheit, Jr., Ph.D. and Karen M. Watson, M.S. presented the results of studies performed with products licensed by ImQuest Life Sciences, Inc. at the recent Microbicides 2008, an international conference held in New Delhi, India and attended by microbicide scientists, developers, and care givers from around the world. Dr. Buckheit was invited to speak by the Conference organizers, presenting the results of ImQuest's current research on the pyrimidinedione series of microbicide candidates in a special symposium entitled "New Approaches to Microbicide Candidates". ImQuest is currently developing the highly unique, dual acting pyrimidinediones as potential microbicide candidates based on their significantly high potency against HIV-1, their unique mechanism of action, and their ability to potently suppress the sexual transmission of wild type and drug resistant viruses.

According to Dr. Buckheit (Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences, Inc., and President of its subsidiary, ImQuest BioSciences, Inc.), "It was highly gratifying to speak on our novel pyrimidinedione products at this Conference and to have them recognized as a new approach to HIV prevention by the thousands of dedicated people leading these efforts around the world." ImQuest has obtained funding from the National Institutes of Health and The International Partnership for Microbicides to further develop these products.

At the conference, Ms. Watson (Manager, Topical Microbicide Research and Development) presented three papers, including additional data on the pyrimidinedione IQP-0528, newly emerging data on the microbicide candidate ISIS 5320 (IQP-0831), and results from laboratory studies performed using ImQuest's recently developed Microbicide Transmission and Sterilization Assay which quantifies the ability of microbicide products to completely suppress the sexual transmission of HIV.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry. Both companies are highly involved in efforts to develop an effective anti-HIV topical microbicide.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.

301-696-0274

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
2. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... PUNE, India , May 26, 2016 ... pain drugs market growth is the emergence of new ... developing astaxanthin therapies for osteoarthritis treatment. The therapy is ... market. Moreover, Arthritis Research UK is conducting studies to ... the arcOGEN study, where the genes involved in osteoarthritis ...
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... , May 25, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 - ... Pump and Others)" published by P&S Market Research, the ... million in 2015, and it is expected to grow ... type, the insulin pump segment is expected to witness ...
Breaking Medicine Technology:
(Date:5/29/2016)... Carolina (PRWEB) , ... May 29, 2016 , ... Whole ... wide jaw clipper that has been available via Amazon.com. This new style of ... thick nails. , The jaw opening is approximately 4mm and the actual handle is ...
(Date:5/28/2016)... , ... May 28, 2016 , ... May 26, 2016- ... Martial Arts Fighting Challenge with theme event of “K Warriors” on June 4, 2016 ... 36608. , The event is sponsored and hosted by Shaolin Institute and sanctioned ...
(Date:5/27/2016)... ... ... Two director-level employees of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... The award recognizes businesswomen who excel in their fields and who have made significant ... Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, Director of ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational ... by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It also ... advocates, associations and industry leaders such as Bioness. , As patients feel ...
(Date:5/27/2016)... ... 2016 , ... Each year Standard Process Inc. ... this year’s Life University winner of a $2,500 scholarship from Standard ... Awards ceremony. , Outerbridge is approaching her last quarter at Life University in ...
Breaking Medicine News(10 mins):